This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
2017 Virtual Symposium: CV Protection: Is It Achievable in Patients with T2DM?

2017 Virtual Symposium: CV Protection: Is It Achievable in Patients with T2DM?



Time to Complete

1 hour


December 19, 2017


December 19, 2018
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE for Nurses (0.80 pharmacotherapy hours)
1.00 / CE for Pharmacists (0.10 CEUs)
1.00 / CPEU for Registered Dietitians

Accredited Provider

This activity is jointly provided by Global Education Group and the Cardiometabolic Health Congress.

Commercial Supporter

This activity is multi-supported by educational grants from Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Program Description

According to 2014 data from the Centers for Disease Control and Prevention, 29.1 million individuals, or 9.3% of the US population, have type 2 diabetes mellitus (T2DM). Death from cardiovascular (CV) disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death.

Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. In addition, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of evidence is accumulating on the ability of certain drugs to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM. This activity will review the prevalence of CV comorbidities in T2DM patients, present new data on the results of recent CVOTs, and discuss approaches to treatment that is targeted to maximizing outcomes in the T2DM patient with CVD.

Intended Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including: physicians (MDs), nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists (ACPE), dieticians (CDR), and other allied health professionals.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Describe the prevalence of CVD among patients with T2DM
  • Outline the benefits and risks of SGLT2 inhibitors and GLP1-RAs in T2DM patients as demonstrated in current and emerging CV outcomes trials
  • Identify a logical addition to existing antihyperglycemic treatment for T2DM patients based on evidence based guidelines, benefits and risks of second-line antihyperglycemic treatments, and patient profiles and preferences

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Jay S. Skyler, MD
Professor of Medicine, Pediatrics, & Psychology
Division of Endocrinology, Diabetes & Metabolism
University of Miami Miller School of Medicine
Deputy Director for Clinical & Academic Programs
Diabetes Research Institute
Miami, FL

Dr. Skyler discloses the following:
Consultant/Independent Contractor: Adocia, AstraZeneca, BD, Boehringer Ingelheim/Eli Lilly Collaboration, Dance Biopharm, DiaVacs, Elcelyx Therapeutics, Genentech, Immnomolecular Therapeutics, Intarcia Therapeutics, Intrexon, Merck, Orgenesis, Sanofi Diabetes, Servier, vTv Therapeutics (Trans Tech), Valeritas
Grant/Research Support: Mesoblast, Viacyte
Ownership Interest/Shareholder: Dance Biopharm, DexCom, Inc., Elizabeth Therapeutics, Ideal Life, Intrexon, Moerae Matrix, Orgenesis, Paean Therapeutics, SynAlpha Therapeutics, VasoPrep Surgical
Board of Directors Member: DexCom, Inc., Elizabeth Therapeutics, Moerae Matrix, Paean Therapeutics, SynAlpha, VasoPrep Surgical.
Scientific Advisory Board Member: Adocia, Intarcia Therapeutics, Intrexon, Sanofi Diabetes, Viacyte
Other/Royalty: Dexcom Inc., Intarcia Therapeutics, Sanofi Diabetes

Wendy S. Lane, MD
Clinical Endocrinologist
Director of Clinical Research
Mountain Diabetes and Endocrine Center
Asheville, NC

Dr. Lane discloses the following:
Consultant/Independent Contractor: Novo Nordisk, Intarcia, Insulet
Grant/Research Support: Novo Nordisk, Eli Lilly, Lexicon Pharmaceuticals, Mylan
Honoraria: Novo Nordisk, Insulet
Speakers Bureau: Novo Nordisk, Insulet

Robert H. Eckel, MD
Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics
Charles A. Boettcher II Chair in Atherosclerosis
Director, T32 in Obesity and Cardiovascular Disease
University of Colorado Anschutz Medical Campus
Director, Lipid Clinic, University Hospital
Aurora, CO

Dr. Eckel discloses the following:
Consultant/Independent Contractor: Sanofi/Regeneron-Expert Witness

Benjamin M. Scirica, MD, MPH
Associate Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Senior Investigator, TIMI Study Group
Brigham and Women’s Hospital/TIMI Study Group
Boston, MA

Dr. Scirica discloses the following:
Grant/Research Support: Dr. Scirica reports research grants via the TIMI Study and Brigham and Women's Hospital from AstraZeneca, Eisai, and Poxel.
Consultant/Independent Contractor: AstraZeneca, Biogen Idec, Boehringer Ingelheim, Covance, Dr. Reddy's Laboratory, Elsevier Practice Update Cardiology, GlaxoSmithKline, Lexicon, Merck, Novo Nordisk, Sanofi, St. Jude's Medical, and equity in Health [at] Scale.

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN, has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Erin Franceschini, MS, has nothing to disclose.
Karin McAdams has nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this virtual activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.




CNE Contact Hour(s)

Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for 1.00 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes 0.80 pharmacotherapy hour.




CE for Pharmacists

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity.

Universal Activity Number (UAN): 0530-9999-17-449-H01-P




CPEU Credit

Accreditation Statement

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statement

CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.

CPE Provider #GE012

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or

If you have any other questions relating to your certificate or other issues with the activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue